Triple Negative Breast Neoplasms Clinical Trial
Official title:
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Withdrawn |
NCT02427581 -
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
|
Phase 1 | |
| Not yet recruiting |
NCT05973864 -
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
|
Phase 3 | |
| Completed |
NCT02789332 -
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
|
Phase 2 | |
| Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
| Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05208762 -
A Study of SGN-PDL1V in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04489940 -
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06154109 -
Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial
|
Phase 2 | |
| Withdrawn |
NCT02539017 -
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT06400472 -
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02720185 -
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
|
Phase 2 | |
| Completed |
NCT03092934 -
A Study of AK-01 (LY3295668) in Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04895709 -
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06380816 -
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06157892 -
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03036488 -
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
|
Phase 3 | |
| Recruiting |
NCT06385990 -
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
|
Phase 2 | |
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 |